Management of gastrointestinal bleeding in patients with cirrhosis of the liver.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016099:Endoscopy, Gastrointestinal; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006471:Gastrointestinal Hemorrhage / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D006975:Hypertension, Portal / Q000209:etiology / Q000628:therapy; D007239:Infections / Q000188:drug therapy / Q000209:etiology; D008103:Liver Cirrhosis / Q000150:complications*; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D011994:Recombinant Proteins / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000209:etiology; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa